Real-world outcomes of trastuzumab deruxtecan as second- or further-line treatment in patients with <i>HER2</i>-mutant metastatic non-small cell lung cancer: a retrospective study.

ABSTRACT:

Background

Real-world data on the application of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC) are scarce. This study observed the effectiveness and safety of T-DXd for the treatment of Chinese patients with HER2-mutant advanced NSCLC in the real-world setting.

Methods

This retrospective study was conducted at two centers in China. Clinical data were reviewed in patients who received T-DXd treatment. The primary outcomes were progression-free survival (PFS) and objective response rate (ORR).

Results

Between April 2023 and January 2025, 35 patients were included. All patients had stage IV lung adenocarcinoma. Median age was 58 years (range, 33-87 years), and 18 (51.4%) patients

SUBMITTER: Huang K 

PROVIDER: S-EPMC12775693 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature